The PharmaSphere: Early-Stage Technology Transfer Collaborations Report provides a cross-section of major licensing deals between mid to large-sized pharmaceutical companies and academic and nonprofit research institutions. This report examines the terms, platform technologies, and deal rationale of 25 pharma-academic alliances from 2012–2013. GlobalData’s Industry Dynamics team of analysts discusses the significant macro-environment drivers which are leading to an increase in research partnerships with academic research institutions on behalf of pharmaceutical companies. We also discuss the unsustainability of the current drug research model, and the industry’s attempts at moving toward an open R&D ecosystem.
Full examination of 25 significant technology transfer deals from 2012 and 2013 involving large pharmaceutical companies and academic organizations including licensing structure and terms
Analysis of the key drivers, trends, and strategies behind the deals undertaken by these pharmaceutical companies across major therapeutic areas
Discussion of the unsustainability of the current drug research model and how Big Pharma’s embrace of collaboration and an open ecosystem could drive the next wave of scientific discovery
Tech Transfer in Action : Each section of the report includes a number of case studies and to highlight major themes within technology transfer
Platform assessment on enabling drug technologies being employed by academic research institutions of interest to pharmaceutical companies
Breakdown of disruptive innovation trends, including open-source patient data, pre-competitive information sharing, ‘Big Data’ and drug recycling/repurposing approaches
Request Sample Pages